Helsinn Advanced Synthesis Successfully Inspected by FDA

Biasca, the Swiss-based APIs (Active Pharmaceutical Ingredients) and HPAPIs (Highly Potent Active Pharmaceutical Ingredients) contract manufacturing company of the Helsinn Group, underwent a successful Inspection by the US-FDA on April 2; the inspection was concluded with "no 483 Observations".

The cGMP Inspection covered all areas involved in the manufacturing of APIs and HPAPIs and involved commercial products as well as the pre-approval inspection for one specific product. The products covered in the FDA inspection are manufactured by Helsinn, on an exclusive basis, for biotech and pharmaceutical companies based in the US.

The Swiss site has been successfully inspected previously by the US-FDA in 1996, 2003 and 2007 without the issue of a 483 Form.

 

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.